Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) plus carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 Article

Full Text via DOI: 10.1093/annonc/mdw383.78 Web of Science: 000393913000370
Industry Collaboration

Cited authors

  • Gajra, A.; Ali, H.; Amiri, K. I.; Karim, N. Abdel; Matrana, M. R.; Mulford, D.; Ong, T. J.; Sanford, A.; Santos, E.; Socinski, M.; Spigel, D. R.; Lilenbaum, R. C.

Publication date

  • 2016

Published in

International Standard Serial Number (ISSN)

  • 0923-7534


  • 27